Research graph
References from Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3390/antib8040055
10.3390/antib8040055 · External reference
10.1038/nri1837
10.1038/nri1837 · External reference
10.1080/19420862.2018.1556465
10.1080/19420862.2018.1556465 · External reference
10.1080/19420862.2019.1703531
10.1080/19420862.2019.1703531 · External reference
10.1038/nbt1137
10.1038/nbt1137 · External reference
10.1186/s12929-024-00996-w
10.1186/s12929-024-00996-w · External reference
10.1038/clpt.2008.170
10.1038/clpt.2008.170 · External reference
10.1186/s12575-017-0060-7
10.1186/s12575-017-0060-7 · External reference
10.3389/fimmu.2018.03037
10.3389/fimmu.2018.03037 · External reference
10.1126/science.180.4088.830
10.1126/science.180.4088.830 · External reference
Antibody therapeutics, antibody engineering, and the merits of protein stability
2008 · External reference
10.1093/protein/gzl016
10.1093/protein/gzl016 · External reference
10.4161/mabs.1.2.7682
10.4161/mabs.1.2.7682 · External reference
10.1016/j.jmb.2005.01.031
10.1016/j.jmb.2005.01.031 · External reference
10.1080/19420862.2016.1214785
10.1080/19420862.2016.1214785 · External reference
10.1016/j.jmb.2006.01.023
10.1016/j.jmb.2006.01.023 · External reference
10.1038/s41467-019-08415-7
10.1038/s41467-019-08415-7 · External reference
Soluble Epstein-Barr virus glycoproteins gh, gl, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion
10.1128/jvi.00572-06 · 2006 · External reference
Natural and non-natural amino-acid side-chain substitutions: affinity and diffraction studies of meditope–Fab complexes
10.1107/s2053230x16016149 · 2016 · External reference
10.1021/acs.bioconjchem.8b00284
10.1021/acs.bioconjchem.8b00284 · External reference
Unresolved reference
2023 · External reference
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment-naive TP53-mutated acute myeloid leukemia: results from the COMMAND consortium
10.1038/s41408-024-01000-2 · 2024 · External reference
10.1093/nar/gkad1084
10.1093/nar/gkad1084 · External reference
10.1080/19420862.2023.2171248
10.1080/19420862.2023.2171248 · External reference
10.1371/journal.pone.0294236
10.1371/journal.pone.0294236 · External reference
10.1016/j.immuni.2018.03.026
10.1016/j.immuni.2018.03.026 · External reference
10.1038/s41467-021-21377-5
10.1038/s41467-021-21377-5 · External reference
10.1002/prot.24554
10.1002/prot.24554 · External reference
10.1016/j.celrep.2020.01.029
10.1016/j.celrep.2020.01.029 · External reference
10.1002/jmr.2418
10.1002/jmr.2418 · External reference
10.1093/bioinformatics/btt055
10.1093/bioinformatics/btt055 · External reference
10.1006/jmbi.1993.1626
10.1006/jmbi.1993.1626 · External reference
10.1002/jcc.20945
10.1002/jcc.20945 · External reference
Unresolved reference
External reference
10.1093/bioinformatics/btr168
10.1093/bioinformatics/btr168 · External reference
10.1016/0263-7855(96)00018-5
10.1016/0263-7855(96)00018-5 · External reference
10.1107/s0907444909047337
10.1107/s0907444909047337 · External reference
10.1107/s2059798319011471
10.1107/s2059798319011471 · External reference
10.1107/s0907444904019158
10.1107/s0907444904019158 · External reference
10.1186/1472-6807-5-14
10.1186/1472-6807-5-14 · External reference
10.3389/fimmu.2021.630034
10.3389/fimmu.2021.630034 · External reference
10.3389/fimmu.2023.1120582
10.3389/fimmu.2023.1120582 · External reference
